Press Releases

15 Nov 2016The Medicines Company and Alnylam Pharmaceuticals Present Positive Results from ORION-1 Phase 2 Study of Inclisiran (formerly PCSK9si)13 Nov 2016Alnylam Pharmaceuticals and The Medicines Company Announce Publication of Phase 1 Clinical Data with Inclisiran (ALN- PCSsc) in the New England Journal of Medicine10 Nov 2016The Medicines Company to Host Conference Call and Webcast to Review Data from Ongoing ORION-1 Phase 2 Study of PCSK9si07 Nov 2016The Medicines Company Discontinues Development of MDCO-216, its Investigational Cholesterol Efflux Promoter26 Oct 2016The Medicines Company Reports Third-Quarter 2016 Financial Results18 Oct 2016The Medicines Company Announces Positive Top-Line Results from Day 90 Interim Analysis in Ongoing ORION-1 Phase 2 Study of PCSK9si17 Oct 2016The Medicines Company to Announce Third Quarter Financial Results on October 26, 201617 Oct 2016The Medicines Company’s Infectious Disease Portfolio Featured in 16 Presentations at IDWeek 201613 Oct 2016The Medicines Company to Present Data from its Investigational Anesthetic MDCO-700 at the ANESTHESIOLOGY® 2016 Annual Meeting and the ISAP 25th Annual Meeting05 Oct 2016The Medicines Company Provides Progress Update on Ongoing ORION-1 Study of PCSK9si21 Sep 2016The Medicines Company Awarded up to $132 Million to Develop Portfolio of New Antibiotics Targeting Drug-Resistant Infections under Strategic Partnership with BARDA30 Aug 2016The Medicines Company Provides Update on Dyslipidemia Programs27 Jul 2016The Medicines Company Reports Second-Quarter 2016 Business and Financial Results18 Jul 2016The Medicines Company to Announce Second Quarter Financial Results on July 27, 201612 Jul 2016Federal Circuit Rules for The Medicines Company in Angiomax® (bivalirudin) Patent Litigation27 Jun 2016The Medicines Company Announces Positive Top- Line Results for Phase 3 TANGO 1 Clinical Trial of CARBAVANCE®21 Jun 2016The Medicines Company Completes Divestiture of its Non-Core Cardiovascular Assets to Chiesi14 Jun 2016The Medicines Company Announces Initiation of Phase II Study for its Investigational Anesthetic, ABP-70013 Jun 2016The Medicines Company Announces Participation at ASM MICROBE 2016 to be held June 16 – 20 in Boston07 Jun 2016The Medicines Company Prices $350 Million of Convertible Notes06 Jun 2016The Medicines Company Announces Intention to Offer $350 Million of Convertible Notes02 Jun 2016The Medicines Company Completes Patient Enrollment for ORION-1 Study of PCSK9si26 May 2016The Medicines Company Announces Completion of Patient Enrollment in Phase 3 TANGO 1 Study of CARBAVANCE® (meropenem-vaborbactam) for Treatment of Complicated Urinary Tract Infections (cUTI)25 May 2016The Medicines Company to Present at Two Upcoming Investor Conferences16 May 2016The Medicines Company Appoints Tony Kingsley as President and Chief Operating Officer09 May 2016The Medicines Company Agrees to Divest Non-Core Cardiovascular Assets to Chiesi Farmaceutici S.p.A.09 May 2016The Medicines Company Reports First-Quarter 2016 Business and Financial Results02 May 2016The Medicines Company to Present at Bank of America Merrill Lynch 2016 Health Care Conference26 Apr 2016The Medicines Company to Announce First Quarter Financial Results on May 9, 201611 Apr 2016FDA Grants Fast Track Status for Investigational Antibiotic CARBAVANCE® (meropenem-vaborbactam)04 Apr 2016The Medicines Company Announces Participation at 2016 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held April 9-12 in Amsterdam28 Mar 2016The Medicines Company Announces Participation at 2016 American College of Cardiology (ACC) Scientific Sessions in Chicago02 Mar 2016The Medicines Company to Present at Cowen and Company 36th Annual Health Care Conference19 Feb 2016The Medicines Company to Participate in 2016 RBC Capital Markets Global Healthcare Conference17 Feb 2016The Medicines Company Reports Fourth-Quarter and Full-Year 2015 Business and Financial Results05 Feb 2016The Medicines Company Announces Clive Meanwell, MD, PhD, Chief Executive Officer, Is the Recipient of the 2016 Dr. Sol J. Barer Award for Vision, Innovation and Leadership04 Feb 2016The Medicines Company to Announce Fourth Quarter and Full Year 2015 Financial Results on Wednesday, February 17, 201603 Feb 2016The Medicines Company Appoints Alexander J. Denner, Ph.D. to its Board of Directors02 Feb 2016The Medicines Company to Participate in Leerink Partners 5th Annual Global Healthcare Conference01 Feb 2016The Medicines Company Completes Divestiture of its Hemostasis Portfolio to Mallinckrodt plc11 Jan 2016The Medicines Company Advances Clinical Development of Investigational First-in-Class PCSK9 Synthesis Inhibitor for Atherosclerotic Cardiovascular Disease (ASCVD)04 Jan 2016The Medicines Company to Participate in J.P. Morgan 34th Annual Healthcare Conference

Contact Us

The Medicines Company
8 Sylvan Way
Parsippany, NJ 07054 USA
Tel 973 290 6000
Toll-free 800 388 1183
Global Medical Information

Human Resources
Verification of employment
Tel 973 290 6361
Fax 862 207 6361

Investors Relations

Krishna Gorti, MD
Tel 973 290 6122
krishna.gorti@themedco.com

Media Inquiries

Michael Blash
Tel 973 290 6100
michael.blash@themedco.com